Vitamin B-based treatment for corneal disease may offer some patients a permanent solution

Patients in the United States who have the cornea-damaging disease keratoconus may soon be able to benefit from a new treatment that is already proving effective in Europe and other regions. The treatment, collagen crosslinking, improved vision in almost 70 percent of keratoconus patients in a recent three-year clinical trial in Milan, Italy. The treatment is in clinical trials in the United States and is likely to receive FDA approval in 2012.

Read the whole article on Science Daily

More from Science Daily